Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, P.R. China.
Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Mol Pharm. 2021 Jul 5;18(7):2482-2494. doi: 10.1021/acs.molpharmaceut.1c00290. Epub 2021 Jun 8.
Dementia is a significant public health problem in the 21st century. Alzheimer's disease (AD) is an essential factor in dementia. Currently, the drugs used for the treatment of AD are mainly acetylcholine inhibitors (AChEIs). As an AChEI, donepezil (DP) can improve patients' cognitive ability with low side effects and has been accepted by most patients and doctors. For AD patients, the dosage regimen is also crucial due to aging and diseases. Although there are DP oral tablets on the market, there are still many problems to be solved. At present, more and more research is conducted to optimize the route of administration of DP to improve the self-administration of patients. The research fields of DP administration include oral administration, injection administration, intranasal administration, and transdermal administration. This Review is to present the development of different DP administrations and evaluates the advantages and limitations of those works, hoping to optimize the DP dosage regimen for AD patients.
痴呆症是 21 世纪的一个重大公共卫生问题。阿尔茨海默病（AD）是痴呆症的重要因素。目前，用于治疗 AD 的药物主要是乙酰胆碱抑制剂（AChEIs）。多奈哌齐（DP）作为一种 AChEI，可改善患者的认知能力，且副作用低，已被大多数患者和医生接受。对于 AD 患者，由于年龄和疾病的原因，剂量方案也很关键。尽管市场上有 DP 口服片剂，但仍有许多问题需要解决。目前，越来越多的研究致力于优化 DP 的给药途径，以提高患者的自我给药能力。DP 给药的研究领域包括口服给药、注射给药、鼻内给药和经皮给药。本综述旨在介绍不同 DP 给药的发展，并评估这些工作的优缺点，希望能优化 AD 患者的 DP 剂量方案。
